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Abstract
Context: Over the past few years, reports of emergence and transmission of drug-resistant strains
of HIV have increased, especially in western countries. In the context of increased widespread use
of zidovudine- and lamivudine-based combinations in India, coupled with the genetic diversity of
HIV, it is essential to generate preliminary data on the frequency of zidovudine- and lamivudine-
resistant variants of HIV-1 in North India.
Objectives: In the present study, the authors screened for mutations in the pol gene of HIV-1
associated with resistance to zidovudine and lamivudine in HIV-infected treatment-naive patients
from North India.
Design and Patients: The mutations were screened at codons 70 and 215 (conferring resistance
to zidovudine) and at codon 184 (conferring resistance to lamivudine) by using a nested
amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) approach from
the proviral DNA of 60 patients.
Results: Most of the patients showed a mixture of both wild-type and mutant virus. In all but 1
patient, wild-type virus was observed with respect to each codon. Mutant variants were also
observed in many patients, especially at codon 70 (48 patients [80%]) and codon 184 (19 patients
[31.67%]). In contrast, the frequency of mutation at codon 215 was found to be very low (1 patient
[1.67%]).
Conclusion: In this sample of treatment-naive HIV-1-infected patients in North India, a high
proportion of mutant variants harbored mutations in the pol gene at codons- 70 and 184 coexisting
with wild-type HIV-1.
Introduction
The emergence and transmission of drug-resistant variants
of HIV-1 can limit the therapeutic options of newly
infected patients. There are several reports on drug resist-
ance in treatment-naive individuals infected with subtype
B of HIV-1 or its recombinants. Reports from North Amer-
ica and Europe indicate that up to 14% of recently
infected patients carry a strain of virus with either well-
characterized drug resistance mutations (in 1% to 10%
cases) or reduced susceptibility to a particular drug (2% to
14% of cases).[1-3] In pregnant women, primary resist-
ance to nucleoside reverse transcriptase inhibitors has
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ing India, where most of the world's HIV-infected patients
and most of those infected with subtype C live, there is
very little information on drug resistance in HIV-infected
people.
The frequency at which drug-resistant reverse transcriptase
variants occur in evolving HIV-1 populations depends on
the mutation frequencies in the pol gene, viral load, and
the number of mutations needed to confer the resistance
phenotype.[5,6] For some drugs, such as zidovudine,
high-level resistance requires accumulation of 3 or more
mutations in a single viral genome (mainly involving
codons 215 and 70 along with codons 210, 219, 41, or
67).[7,8] In other drugs, such as lamivudine, a single
mutation (at codon 184) can confer high-level resistance
and drug-resistance mutations can be established within
weeks. The mutations associated with primary resistance
persist for at least 7 years; however, M184V/I mutation
may revert after 1 year because of reduced replication fit-
ness.[9]
Our study was designed to obtain preliminary data on the
frequency of drug-resistant variants of HIV-1 in a North
Indian population. We performed genotyping in 60 treat-
ment-naive patients to detect primary mutations associ-
ated with resistance to zidovudine, lamivudine, or both in
the pol gene of HIV-1. We used a highly sensitive nested
amplification refractory mutation system-polymerase
chain reaction (ARMS-PCR) approach, which allowed us
to identify the minority population of the virus harboring
these mutations among the predominant wild-type popu-
lation. In the case of zidovudine, we targeted the 2 most
common resistance-associated mutations at codons 70
and 215 of the pol gene, while for lamivudine we chose
codon 184 to detect mutations.
Materials and methods
Patient Recruitment
Mutation studies were performed in 60 consecutive HIV-
1-infected individuals from North India who came to a
voluntary counseling and testing center in the Depart-
ment of Immunopathology, Post Graduate Institute of
Medical Education and Research, Chandigarh, India, for
testing and routine measurement of CD4+/CD8+ cell
counts between January 2000 and December 2002.
Patients were randomly recruited without any disease sta-
tus bias. None of the patients had received any antiretro-
viral therapy before the beginning of the study. The age of
the patients ranged from 1 -to 67 years (mean, 30.8 ± 11.5
years). Twenty-nine men, 23 women (none of whom were
pregnant), and 8 children were recruited. The patients'
mean CD4+ cell count was 276.7 ± 238.1 cells/mcL, while
their mean CD8+ cell count was 999.1 ± 598.4 cells/mcL.
The mean CD4+/CD8+ ratio was 0.28 ± 0.22. Thirty
patients had CD4+ cell counts above 200 cells/mcL, and
30 patients had CD4+ cell counts below 200 cells/mcL.
After written consent was obtained from each patient,
blood was drawn in a K3 EDTA Vacutainer (Becton, Dick-
inson and Company, Franklin Lakes, New Jersey) and was
centrifuged at 2500 rpm for 10 minutes to separate
plasma and buffy coat (consisting of leukocytes).
DNA Extraction and pol Gene Amplification
DNA was extracted from leukocytes with some modifica-
tions.[10] In the first PCR, extracted DNA was used to
amplify a 768 bp fragment of the pol gene (encompassing
codons 70, 184, and 215) using primers POL Pr-1 and
POL Pr-2.[11] We modified the primers as published for
clade- B according to the sequences of consensus regions
in the pol gene of HIV-1 clade C isolates from India[12] by
extending their 3' ends.
Identification of Mutations (ARMS-PCR)
An amplified pol gene fragment (768 bp) was used as the
template to detect wild and mutant sequences at codon
184 by ARMS-PCR using codon-specific primers. Briefly,
the downstream primers, 184W, 184G, and 184I, were
paired separately with 184U as the common upstream
primer to detect the codons Met (wild), Val (mutant), and
Ile (mutant), respectively, at codon 184 of the pol
gene.[13] Mutations at codons 70 and 215 were also ana-
lyzed in a similar manner,[11] using primers modified
from previously published sequences.[12] The PCR prod-
ucts were separated on 2% agarose gel (Sigma; Saint Louis,
Missouri) and documented in a gel documentation sys-
tem (Image Master VDS; Pharmacia Biotech; Sweden).
The sequences (5'  3') of the primers (custom synthesized
from SigmaGenosys; The Woodlands, Texas) were as fol-
lows:
POL Pr-1: TTC CCA TTA GTC CTA TTG AAA CTG T
POL Pr-2: TCA TTG ACA GTC CAG CTA TCC TTT T
184U: TAC AAT GTG CTT CCA CAG GG
184W: TCC TAC ATA CAA ATC ATC CAT
184G: CCT ACA TAC AAA TCA TCC AC
184I: GAT CCT ACA TAC AAA TCA TCT
Pr-2W: CT GAA ATC TAC TAA TTT TCT CCA CT
Pr-2M: CT GAA ATC TAC TAA TTT TCT CCA CC
Pr-B: GGA TGG AAA GGA TCA CCA GCAPage 2 of 7
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Pr-3M: TGA TGT TTC TTG TCT GGT GTG AA
The amplification of the pol gene and subsequent detec-
tion of wild/mutant sequences at codons 70, 184, and 215
in the pol gene were cross-checked by using a wild-type
control (clone of HIV-1 subtype C in pNL4-3 vector, pro-
vided by Dr. Vijay Chaudhary, Department of Biochemis-
try, Delhi University, New Delhi, India). Also, to check
whether the primers used in our study were sensitive
enough to detect the subtype B strain of HIV as well, we
used another clone of HIV-1 subtype B, cloned in pNL4-3
vector and provided by Dr. Shahid Jameel, International
Centre for Genetic Engineering and Biology, New Delhi,
India.
Sequencing
The amplified pol gene fragments of 10 representative
samples were subjected to sequencing and were analyzed.
The PCR products were purified by using a PCR product
purification kit (Invitek; Berlin, Germany) according to
the manufacturer's instructions. The purified PCR prod-
ucts were sequenced with the forward primer Pol F1 (5'-
GCC TGA AAA TCC ATA TAA CAC TCC-3') on an auto-
mated DNA sequencer (ABI Prism 3100, version 3.0,
Applied Biosystems Inc., Foster City, California) using the
Big Dye terminator cycle sequencing kit (version 3.1) sup-
plied by Applied Biosystems.
Statistical Analysis
We used the chi-square test (2 test) to analyze the signifi-
cance of appearance of mutations at different codons in
correlation with CD4+ cell counts and patients' age. The
significance of appearance of mutations among men,
women, and children was analyzed by using 1-way analy-
sis of variance.
Results
Mutations at Codon 184
Point mutations at codon 184 (MetVal/Ile) in the pol gene
of HIV are known to confer high-level resistance to lami-
vudine. While amplification of wild-type sequence (Met)
was observed in all of the patients, 19 patients (31.67%)
also showed presence of mutant variants (Val, Ile, or
both) as well. Of these patients, 16 (84%) showed the
presence of both Val and Ile variants (26.67% of the total
patients) and 3 (16%) showed Val (5.0% of the total
patients) coexisting with the wild type (Table 1).
Mutations at Codon 215
Mutation at codon 215 (ThrPhe) is known to be associ-
ated with resistance to zidovudine as one of the primary
mutations. In case of codon 215, all patients showed the
presence of wild-type virus. Mutation was seen in only 1
patient, indicating a very low frequency (1.67%) (Table
1).
Mutations at Codon 70
Mutation at codon 70 (Lys Arg) is also known to be one
of the primary mutations associated with resistance to
zidovudine. Of the 60 patients, 47 (78.33%) showed a
mixture of both wild and mutant types of the virus, while
1 patient (1.67%) showed only the mutant type of the
virus carrying the codon 70 mutation (Table 1).
The PCR products of each codon are shown in the Figure.
Sequence Analysis
The sequences of all of the samples were analyzed by
using the ClustalX alignment software, version 1.81. The
amplified pol gene sequences of all the 10 samples showed
the presence of wild-type sequence at codons 70, 184, and
215, indicating that these were predominantly available
variants.
Correlation of Appearance of Mutations with CD4+ Cell 
Counts, Age, and Sex of Patients
Nineteen patients had lamivudine-associated mutations.
Of these 19 patients, 10 had CD4+ cell counts below 200
cells/mcL and 9 had CD4+ cell counts above 200 cells/
mcL (Table 2). There was no significant correlation
between the appearance of mutations at codon 184 and
CD4+ cell counts in these patients (2 = 0.077; P > .05). Of
the 48 patients showing zidovudine-associated mutations
at codon 70, 23 had CD4+ cell counts below 200 cells/
Table 1: Composite Mutation Profile of the 60 Patients, at Different Codon Positions in the pol Gene
Codon Position Resistance to Drug Number of Patients With 
Wild Type
Number of Patients With 
Mutation Type
Proportion of Patients 
Showing Mutations
184 Lamivudine 60 (Met) 19 (16: Val & Ile) (3: Val only) 31.67%
215 Zidovudine 60 (Thr) 1 (Phe) 1.67%
70 Zidovudine 59 (Lys) 48 (Arg) 80%Page 3 of 7
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which is again nonsignificant (2 = 0.157 P > .05). With
respect to age, there were 39 patients above the mean age
(ie 30.8 ± 11.5 years) and 21 patients below it; of the latter
group, 8 were children. The relationship between the age
of patients and the appearance of mutations at codons 70
(2 = 2.41; P > .05) and 184 (2 = 0.307; P > .05), respec-
tively, was also found to be nonsignificant. However, for
codon 70, the mutation frequency in children was low
compared with adults (1-way analysis of variance = 0.03;
P < .05).
When we compared the appearance of mutations at
codons 70 and 184 between men and women, the differ-
ence in appearance of mutations was nonsignificant (P >
.05), indicating no relation with sex.
Discussion
In a country where an estimated 5.1 million people are
living with HIV, information on the prevalence as well as
the transmission of drug-resistant HIV strains would aid
design of optimal drug regimens and clinical manage-
ment. Our study was designed to obtain preliminary data
on the frequency of drug-resistant variants in a treatment-
naive North Indian population. The study involved
patients from North Indian states (Punjab, Haryana,
Himachal Pradesh, Jammu and Kashmir, and Chandi-
garh) who were not taking any antiretroviral drugs. We
performed genotyping to detect mutations associated
with resistance to zidovudine and lamivudine, the most
common first-line drugs administered in India, as well as
the rest of the world as part of antiretroviral regimens. We
used a highly sensitive, nested ARMS-PCR approach to
detect these mutations so that the minority population of
the virus harboring the mutations could be detected
among the predominant wild-type population.
The mutation T215F causes intermediate (about 10-fold)
resistance to zidovudine. The point mutation K70R causes
low-level (4- to 5-fold) resistance to zidovudine and is
usually the first drug resistance mutation to develop in
patients receiving zidovudine monotherapy.[14,15]
Table 2: Characteristics of Patients With Respect to Mutations Observed in the pol Gene
Mutation 
Position
Age CD4+ Cell Counts Gender
< 30.8 years 
(n = 32)
> 30.8 years 
(n = 28)
< 200 cells/
mcL (n = 30)
> 200 cells/
mcL (n = 30)




Codon 184 11 8 10 9 10 7 2
Codon 70 28 20 23 25 24 21 3
Codon 215 0 1 1 0 1 0 0
Table 3: Pol Gene Mutation Profile in Different Countries as Observed by Different Groups
Country Codon 70 (K70 R) Codon 215 (T215 F/Y) Codon 184 (M184V/I)
Spain[6] 22.8% 0
Israel[22] -- 100% (clade B) 7/14 in clade B
0/20 in clade C
United States (infants)[21] 199294 = 6.3%
199899 = 33.3%
Poland[29] 81.8% 33.3%
Ivory Coast[34] 39.7% to any of the NRTI drugs
Martinique (French West Indies)[24] 17.15% 2.85% 5.71%
Present study (North India) 80% 1.67% 31.67%
NRTI = nucleoside reverse transcriptase inhibitor.Page 4 of 7
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their effect on zidovudine resistance and rarely occur
together unless additional nucleotide excision mutations
are present.[16] Both K70R and T215F cause reproducible
reductions in zidovudine susceptibility regardless of the
susceptibility assay used. Until recently, zidovudine mon-
otherapy was also offered to HIV-infected patients and
pregnant women to stop vertical transmission.[17] The
data obtained from our study revealed a low frequency of
codon 215 mutations (1.67%) compared with codon 70
(80%) and codon 184 (31.67%). The fact that codon 215
mutations have a relatively low level of fitness may
explain their low frequency.[18] Moreover, the codon 215
mutation involves substitution of 2 bases (ACCTTC).
Prevalence of these mutations is also very low worldwide,
varying between 1% and 8% in treatment-naive HIV-
infected populations.[3,19,20] However, in a US study of
mother-to-child transmission, the authors investigated
codon 215 mutation by nested PCR approach in 49 HIV-
1-infected infants born between 1992 and 1999.[21] They
observed that 6.3% of the infants born between 1992 and
1994 showed codon 215 mutation but that this figure
increased to 33.3% in infants born between 1998 and
1999 (Table 3). In a comparative study in Israel of geno-
typic variation of reverse transcriptase between clade C
and clade B strains of HIV-1, the authors reported a 100%
mutation rate (T215F/Y) at codon 215 in 14 patients who
had clade B strain. However, none of the 20 patients with
clade C isolates carried the codon 215 mutation.[22] This
indicates that mutations at codon 215 are more prevalent
in clade B than in clade C. In another study, reverse tran-
scriptase mutations M41L, L210W, and, to a lesser extent,
T215Y were less prevalent in patients infected with non-B
variants[23]. In some parts of the world, the transmission
of codon 215 mutant variants has decreased, possibly
because of the use of improved regimens.[20] Such stud-
ies highlight the fact that significant genotypic variation
may occur in certain regions of the reverse transcriptase
gene of clade C and clade B strains of HIV. In Africa, South
America, and the Caribbean, he prevalence of HIV strains
with at least 1 primary drug-resistant mutation is low (less
than 7%), as evidenced by a few reports on drug resistance
based on sequencing of the pol gene.[24-28] In Africa and
South Asia (including India), where most of the world's
HIV-infected patients and most of those infected with
subtype C live, there is very little information on drug
resistance in HIV-infected people. With recent increases in
the use of zidovudine-based combinations in India, future
studies on this issue should assess the transmission pat-
tern of clade C drug-resistant variants, which are prevalent
in India.
In contrast to codon 215, the results of codon 70 PCR
paint an intriguing picture. Of the 60 patients, 78.33%
showed mutant variants coexisting with the wild type,
while 1 patient (1.67%) carried pure mutant type (K70R).
Many reports on drug resistance-associated mutations in
treatment-naive patients have been published, but none
of them have reported such high levels of codon 70 muta-
tion. This may be because most of these studies have
reported the genotype of the virus isolated from the
plasma by sequencing methods, which normally detect
the predominant viral population in the circulation and
may miss the minority viral populations that may harbor
the mutations. However, a study from Warsaw, Poland,
has also reported high percentage of codon 70 mutations
in treatment-naive patients. The authors identified K70R
mutation in 54 of 66 patients (81.8%) and an M184V
mutation in 22 cases (33.3%) by using a line-probe
assay[29] (Table 3). In another study from Martinique in
the French West Indies, genotypic resistance was studied
by using a line-probe assay in samples of plasma HIV RNA
collected between 1988 and 1998 from 70 antiretroviral-
naive patients.[24] Most of these patients showed a mixed
population, and 17 harbored mutated viruses with 1 or
more mutations in the reverse transcriptase gene codons
A 2% agarose gel stained with ethidium bromide showing products of codon-specific PCRs from a patient's p l gene fragmentFigur  1
A 2% agarose gel stained with ethidium bromide 
showing products of codon-specific PCRs from a 
patient's pol gene fragment. The patient showed wild-
type and mutated codons at position 70 (227 bp fragment in 
lanes 70 W and 70 M), wild type at codon 215 (210 bp frag-
ment in lane 215 W), and both mutations along with wild 
type at codon 184 (134 bp fragment in lanes 184 W, 184M1, 
and 184M2). Mr: Molecular weight marker (phi X174, Hae III 
digested).
70C 70W 70M 215C 215W 215M 184C 184W 184M1 184M2 Mr.Page 5 of 7
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M41L, and K70R were found in 2, 5, and 12 individuals,
respectively. Mutant strains of M184V were detected in 4
patients.
The results of codon 70 and 215 in our study have also
confirmed that both these mutations rarely coexist.
Although these mutant variants were present along with
wild-type virus, such mutations would always be a threat
to antiretroviral therapy because they are the reservoirs of
phenotypic resistance to zidovudine. Regular resistance
genotyping of patients with such mutations thus becomes
important once patients begin antiretroviral therapy.
Another important mutation detected in our study popu-
lation was M184V/I, which is usually the first to develop
in isolates from patients receiving lamivudine-containing
regimens.[13] Considering that all of the patients were
treatment-naive, the proportion of patients showing
mutant variants (31.67%) still represents a high number
even though all of them also had wild-type virus. Other
studies have reported mutation rates of codon 184 rang-
ing from of 2%,[3] 7%,[30], and 5%[1] in the United
States to as high as 33.3% in Poland[29] among treat-
ment-naive HIV-infected patients.
In contrast to the results of ARMS-PCR, the results of
sequencing showed the presence of wild-type sequence at
codons 70, 184, and 215 as observed in the few represent-
ative samples, indicating this to be the predominant vari-
ety. Therefore, to confirm whether the results obtained by
ARMS-PCR were correct, we used another approach. We
used the clones of HIV-1 subtype B and subtype C that
were pure for the wild type. None of these clones showed
amplification of mutant sequence in the PCR reactions of
codons -70, 184, and 215. This indicates that the muta-
tions seen in the patient samples represented the minority
population of the total viral population, which is predom-
inantly of the wild type. Such variations in the sequencing
versus other genotyping approaches have been observed
earlier as well; the available sequencing assays have been
shown to identify only the resistance profile of the pre-
dominant viral variant in the infected patient.[6,31]
Moreover, it has also been shown that the targeted geno-
typing approaches are much more sensitive than the com-
mon sequencing approaches.[32,33] In one such study,
the sensitivity and discriminatory power of the ARMS-
PCR were evaluated, and their performance for the detec-
tion of drug resistance at codons 151 and 215 in mixed
genotypic populations of the reverse transcriptase gene of
HIV-1 were compared with T7 cycle sequencing, the line
probe assay, and the recombinant virus assay. [33] The
line-probe assay and ARMS-PCR detected minor variants
that in particular cases made up only 1% of the viral pop-
ulation.
In conclusion, our study indicates that the proportion of
mutant variants harboring mutations in the pol gene at
codons 70 and 184 coexisting with wild-type HIV-1 is
high in treatment-naive patients in North India. The
appearance of these mutations had no correlation with
CD4+ cell counts or sex of the patients, although mutant
variants seemed to be less common in children. Finally,
the genetic diversity of HIV suggests that targeted genotyp-
ing resistance assays applicable for different HIV-1 sub-
types can be used to determine HIV drug resistance in
different parts of the world.
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